Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Bellerophon Therapeutics (Nasdaq: BLPH) announced that CEO Fabian Tenenbaum will provide a corporate overview at the H.C.

Rhea-AI Summary

Bellerophon Therapeutics (Nasdaq: BLPH) announced that CEO Fabian Tenenbaum will provide a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, taking place from September 13-15, 2021. The presentation will be available on-demand starting at 7:00 AM ET on September 13, accessible via the Investors section of the company's website.

Bellerophon focuses on innovative therapies for cardiopulmonary diseases and is developing multiple candidates under the INOpulse® program, a proprietary nitric oxide delivery system.

Argus Publication session

+2.51% session move Open Argus

Details

News Market Reaction – BLPH

In the trading session that priced this news, BLPH gained 2.51%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23^rd Annual Global Investment Conference, being held September 13-15, 2021.

The presentation will be available on-demand beginning at 7:00 AM Eastern Time on Monday, September 13, 2021, in the Investors section on the Company’s website at www.bellerophon.com.

About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse^® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.

Contacts
LifeSci Advisors:
Brian Ritchie
(212) 915-2578
britchie@lifesciadvisors.com                                                

 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Bellerophon Therapeutics present at the H.C. Wainwright Conference?

Bellerophon Therapeutics will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.

What time will Bellerophon’s presentation be available?

The presentation will be available on-demand starting at 7:00 AM ET on September 13, 2021.

Where can I watch Bellerophon Therapeutics' presentation?

You can watch the presentation in the Investors section of Bellerophon Therapeutics' website.

What does Bellerophon focus on?

Bellerophon Therapeutics focuses on developing innovative therapies for cardiopulmonary diseases.

What program is Bellerophon currently developing?

Bellerophon is currently developing multiple product candidates under its INOpulse® program.